Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × GastroEsophageal Cancer × Lapatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 73 Neoplasms 14 Neoplasm Metastasis 12 Brain Neoplasms 9 Breast Neoplasms, Male 7 Stomach Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Head and Neck Neoplasms 4 Prostatic Neoplasms 3 Inflammatory Breast Neoplasms 3 Colorectal Neoplasms 3 Carcinoma, Squamous Cell 3 Urinary Bladder Neoplasms 2 Salivary Gland Neoplasms 2 Recurrence 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Gallbladder Neoplasms 2 Ependymoma 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Tongue Neoplasms 1 Thymoma 1 Spinal Cord Neoplasms 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Patient Compliance 1 Osteitis Deformans 1 Neuroma, Acoustic 1

Interventions

Lapatinib 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01145404 2014-07-02

GastroLap

National Center for Tumor Diseases, Heidelberg

Phase 2 Terminated

Gastrointestinal

GastroEsophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡